Clin Cancer Res:基因组不稳定性是侵袭性前列腺癌的区别性特征

2020-05-08 AlexYang MedSci原创

侵袭性变体前列腺癌(AVPC)代表着一种临床亚型,可以通过治疗抗性和不良预后区分,并且与肿瘤抑制基因(TSG)PETN、RB1和TP53丧失有关。循环肿瘤细胞(CTC)为AVPC的最小侵入性鉴定和分子

侵袭性变体前列腺癌(AVPC)代表着一种临床亚型,可以通过治疗抗性和不良预后区分,并且与肿瘤抑制基因(TSG)PETN、RB1和TP53丧失有关。循环肿瘤细胞(CTC)为AVPC的最小侵入性鉴定和分子解析提供了途径。最近,有研究人员评估了前列腺癌CTC复杂的(2+)TSG丧失和基因组不稳定性的发生率以及临床意义,并扩展了与AVPC有关的基因组生物标记。

研究人员对47名患者(每名患者1-22 CTC)的257个CTC进行了测序。研究发现,20名患者(42.6%)中至少有1个CTC同时具有2+TSG丧失,并且与不良生存和基因组不稳定性的增加相关,这也可以通过高的大规模转移评分(LST)推断。CTC中更高的LST与所列举的CTC无关,在临床上比共发的TSG丧失更能说明侵袭性行为,并且在分子上与染色体区域的增益有关,包括PTK2、Myc和NCOA2,雄激素受体(AR)表达增加,以及BRCA2丧失。在游离肿瘤DNA匹配的57名患者数据中,CTC在CAN分析中更容易检测和评估(分别为73.7% vs 42.1%)。

最后,研究人员指出,他们发现表明了CTC基因组不稳定性是晚期前列腺癌侵袭的标志,支持了单个CTC测序进行非侵入鉴定癌症异质性的一种令人信服的工具。

原始出处:

Paymaneh D Malihi , Ryon P Graf , Angel Rodriguez et al. Single-cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer. Clin Cancer Res. 27 April 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1900529, encodeId=472c1900529d6, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Thu Apr 22 22:12:10 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006233, encodeId=6752200623332, content=<a href='/topic/show?id=9307418196e' target=_blank style='color:#2F92EE;'>#基因组不稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41819, encryptionId=9307418196e, topicName=基因组不稳定性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Mon Feb 22 05:12:10 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366365, encodeId=903c1366365b4, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sun May 10 04:12:10 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040738, encodeId=fa7d1040e3825, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri May 08 16:12:10 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1900529, encodeId=472c1900529d6, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Thu Apr 22 22:12:10 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006233, encodeId=6752200623332, content=<a href='/topic/show?id=9307418196e' target=_blank style='color:#2F92EE;'>#基因组不稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41819, encryptionId=9307418196e, topicName=基因组不稳定性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Mon Feb 22 05:12:10 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366365, encodeId=903c1366365b4, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sun May 10 04:12:10 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040738, encodeId=fa7d1040e3825, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri May 08 16:12:10 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1900529, encodeId=472c1900529d6, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Thu Apr 22 22:12:10 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006233, encodeId=6752200623332, content=<a href='/topic/show?id=9307418196e' target=_blank style='color:#2F92EE;'>#基因组不稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41819, encryptionId=9307418196e, topicName=基因组不稳定性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Mon Feb 22 05:12:10 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366365, encodeId=903c1366365b4, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sun May 10 04:12:10 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040738, encodeId=fa7d1040e3825, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri May 08 16:12:10 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
    2020-05-10 sunyl07
  4. [GetPortalCommentsPageByObjectIdResponse(id=1900529, encodeId=472c1900529d6, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Thu Apr 22 22:12:10 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006233, encodeId=6752200623332, content=<a href='/topic/show?id=9307418196e' target=_blank style='color:#2F92EE;'>#基因组不稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41819, encryptionId=9307418196e, topicName=基因组不稳定性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Mon Feb 22 05:12:10 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366365, encodeId=903c1366365b4, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sun May 10 04:12:10 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040738, encodeId=fa7d1040e3825, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri May 08 16:12:10 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
    2020-05-08 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

前列腺癌治疗新进展!即将开展EPI-7386的临床研究

专注于研发前列腺癌新疗法的制药公司ESSA今日宣布,美国FDA允许ESSA继续进行EPI-7386的临床研究,以治疗转移性去势抵抗性前列腺癌(mCRPC)。

AACR 2020:PD-L1+恩杂鲁胺治疗去势抵抗性前列腺癌,未获成功

IMbassador250 III研究纳入了阿比特龙治疗失败的晚期去势抵抗性前列腺癌患者,随机分为PDL1单抗Tecentriq +恩杂鲁胺组或恩杂鲁胺组。

N Engl J Med:奥拉帕尼治疗转移去势抵抗性前列腺癌研究

在前列腺癌和其他癌症患者中,与DNA修复(包括同源重组修复)有关基因的多个基因功能丧失变异与聚(二磷酸腺苷-核糖)聚合酶(PARP)抑制剂响应相关。

Eur Urol:前列腺癌中的标准化和简化机器人辅助超扩展盆腔淋巴结清扫术

在经历根治性前列腺切除术(RP)的中等风险和高风险前列腺癌(PCa)患者中,扩展盆腔淋巴结清扫术(ePLND)仍旧是淋巴结分期最准确的方法。而在非常高风险PCa患者中可以考虑使用超扩展盆腔淋巴结清扫术

Eur Urol:恩杂鲁胺雄激素阻断治疗联用对转移激素敏感性前列腺癌患者健康相关生活质量影响研究

ARCHES研究中的转移激素敏感性前列腺癌(mHSPC)中,与单独的ADT治疗相比,恩杂鲁胺与雄激素阻断治疗(ADT)联用能够改善影像学无进展生存(rPFS)。最近,有研究人员评估了长达73周的患者报

JAMA Oncol:高强度放射或延缓前列腺癌扩散患者病情

最近,美国研究人员在《美国医学会杂志—肿瘤学》上发表的一项研究报告称,高精度、高强度的立体定向消融放射(SABR)可能延缓部分已扩散到体内的前列腺癌患者病情。